Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

BACKGROUND. Endocrine therapy resistance in hormone receptor-positive (HR+) breast cancer (BC) may involve crosstalk between HRs and growth factor signaling pathways. We evaluated bosutinib, a dual Src/Abl tyrosine kinase inhibitor that has previously demonstrated some antitumor activity in BC, plus...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2014
Teme:
Clinical Trial Results
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983830/
https://ncbi.nlm.nih.gov/pubmed/24674874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0021
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items